Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An open-label, U.S. Phase III trial in 200 healthy volunteers showed that 0.5 mL subcutaneous BioThrax on days
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury